What Is the True Mortality Benefit of Prostate-Specific Antigen Screening?

[摘要] The European Randomized Study of Screening for Prostate Cancer (ERSPC) included 7 European countries and randomized a total of 162,243 men aged 55 to 69 years to screening and control arms.1 In the intentto-treat (ITT) analysis, Schröder and colleagues previously reported a 20% reduction in prostate cancer-specific mortality with screening (relative risk [RR] 0.80; 95% confidence interval [CI], 0.65–0.98; P = .04), as we have previously reviewed.2

[学科分类] 基础医学